Get started
Author

G. Illei

Macrophage‐derived cytokine and nuclear factor κB p65 expression in synovial membrane and skin of patients with psoriatic arthritis
2000 · C. L. Danning, G. G. Illei, et al. · Arthritis & Rheumatism · 217
Identification of parotid salivary biomarkers in Sjögren's syndrome by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry and two-dimensional difference gel electrophoresis
2006 · O. H. Ryu, J. C. Atkinson, et al. · Lara D. Veeken · 215
Use of a novel virus detection assay to identify coronavirus HKU1 in the lungs of a hematopoietic stem cell transplant recipient with fatal pneumonia
2011 · C. Uhlenhaut, J.I. Cohen, et al. · Transplant Infectious Disease · 39
PDF
Genetic association between methyl-CpG binding protein 2 (MECP2) and primary Sjögren's syndrome
2010 · Beth L Cobb, Yiping Fei, et al. · Annals of the Rheumatic Diseases · 34
PDF
OP0291 Anifrolumab, An Anti-Interferon-Alpha Receptor Monoclonal Antibody, in Moderate To Severe Systemic Lupus Erythematosus (SLE)
2016 · R. Furie, J.T. Merrill, et al. · Annals of the Rheumatic Diseases · 21
Experience with experimental biological treatment and local gene therapy in Sjögren's syndrome: implications for exocrine pathogenesis and treatment
2006 · B M Lodde, B J Baum, et al. · Annals of the Rheumatic Diseases · 13
OP0174 Alteration of mediators of vascular inflammation by anifrolumab in the phase iib muse study in sle
2018 · W.I. White, N.L. Seto, et al. · Annals of the Rheumatic Diseases · 7
PDF
OP0001 The lupus low disease activity state (LLDAS) definition discriminates responders in a systemic lupus erythematosus (SLE) trial: post-hoc analysis of the phase iib muse trial of anifrolumab
2017 · E Morand, A Berglind, et al. · Annals of the Rheumatic Diseases · 5
PDF
THU0295 Anifrolumab Reduces Disease Activity in Multiple Organ Domains in Moderate To Severe Systemic Lupus Erythematosus (SLE)
2016 · J.T. Merrill, R. Furie, et al. · Annals of the Rheumatic Diseases · 4
OP0020 Identification of Multiple Sjögren's Syndrome Susceptibility Loci
2013 · C.J. Lessard, H. Li, et al. · Annals of the Rheumatic Diseases · 4
Op0120 Duration of Clinical Efficacy Following Treatment With Vib4920 in Subjects With Moderate to Severe Rheumatoid Arthritis
2021 · O. Ali, L. Wang, et al. · Annals of the Rheumatic Diseases · 3
OP0044 Systemic Lupus Erythematosus (SLE) Responder Index [SRI(4)] Response Is Associated with Global Benefit in Patients with Moderate To Severe SLE
2016 · R. Furie, L. Wang, et al. · Annals of the Rheumatic Diseases · 2
AB0183 The Effect of Geography on the Efficacy of Sifalimumab, an Anti-Interferon-Alpha Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus
2015 · M. Khamashta, G. Illei, et al. · Annals of the Rheumatic Diseases · 2
SAT0243 Exposure-response (E-R) analysis for selection of optimal dosage regimen of anifrolumab in patients (PTS) with systemic lupus erythematosus (SLE)
2017 · LC Santiago, B Wang, et al. · Annals of the Rheumatic Diseases · 1
PDF
OP0165 Beneficial Effects of An Anti-Ifnar1 Monoclonal Antibody on Immune Cell Dysregulation and Complement System Abnormalities of Systemic Lupus Erythematosus: An Exploratory Analysis of Phase IIB Clinical Trial of Anifrolumab
2016 · X. Guo, L. Wang, et al. · Annals of the Rheumatic Diseases · 1
AB0189 Geographic Differences in Demographics, Clinical Characteristics, and Standard of Care in Multinational Studies of Patients with Moderate to Severe Sle
2015 · R. Furie, M. Khamashta, et al. · Annals of the Rheumatic Diseases · 1
SAT0220 Effects of type I interferon inhibition on blood leukocyte subsets in patients treated in a phase IIB clinical study of anifrolumab in systemic lupus erythematosus (SLE)
2017 · W White, KA Casey, et al. · Annals of the Rheumatic Diseases
PDF
OP0301 Type i ifn gene signature test–high and –low patients with moderate to severe sle disease activity have distinct gene expression signatures of immunologic pathways and cell types
2017 · H Liu, B Higgs, et al. · Annals of the Rheumatic Diseases
PDF
7 Utility of the lupus low disease activity state (LLDAS) definition in discriminating responders in the phase IIB muse trial of anifrolumab in systemic lupus erythematosus
2017 · E Morand, A Berglind, et al.
PDF
Do anti-mullerian hormone levels predict ovarian reserve in SLE patients presenting for hematopoietic stem cell transplant?
2007 · H. Browne, A. Armstrong, et al. · Fertility and Sterility
PDF
[Relation between symptomless inflammation of the parovarium and unsuccessful tocolysis].
1985 · B Horváth, A Turay, et al. · PubMed
[Immunologic relation between mother and conceptus].
1982 · G Illei · PubMed
Book Reviews
1976 · S.G. Tan, G.C. Ashton, et al. · Human Heredity
PDF
[The behavior of the immunoglobulin level during administration of oral contraceptives].
1970 · T Pulay, C Kovács, et al. · PubMed
Works count: 25
Citation count: 569
H-index: 7
I10-index: 6
Year
Topic
Type